Ten-Year Data from CheckMate -067 Trial Shows Long-Term Survival Benefits of Opdivo ...
The CheckMate -067 trial showed 10-year survival improvements with Opdivo (nivolumab) plus Yervoy (ipilimumab) or Opdivo monotherapy vs. Yervoy monotherapy in advanced melanoma, with median OS of 71.9 months, 36.9 months, and 19.9 months, respectively. The combination therapy demonstrated a 58.3% objective response rate after 10 years, with no new safety signals.
Related Clinical Trials
Reference News
Ten-Year Data from CheckMate -067 Trial Shows Long-Term Survival Benefits of Opdivo ...
The CheckMate -067 trial showed 10-year survival improvements with Opdivo (nivolumab) plus Yervoy (ipilimumab) or Opdivo monotherapy vs. Yervoy monotherapy in advanced melanoma, with median OS of 71.9 months, 36.9 months, and 19.9 months, respectively. The combination therapy demonstrated a 58.3% objective response rate after 10 years, with no new safety signals.